Nanostrategies in the war against multidrug resistance in
leukemia
Review
Article
AUTHORS: Alphy Rose-James1, TT
Sreelekha1, Suraj K. George2*
AFFILIATIONS: 1Laboratory of
Biopharmaceuticals, Division of Cancer Research, Regional Cancer Centre,
Thiruvananthapuram-695 011, Kerala , India
* CORRESPONDING AUTHOR: Dr. Suraj Konnath George PhD. Dept. of
Hematopathology. Division of Pathology and Laboratory Medicine. University of Texas Anderson Cancer Center 1515 Holcombe Blvd, Houston , TX 77030 , USA . Ph: 001-7137927692 Fax: 001-7137927273. Email: skonnath@mdanderson.org or surajrcc@gmail.com
Chemotherapy is the cornerstone of treatment for
haematological malignancies. Despite innovative advances in the understanding
of this complex disease, multidrug resistance (MDR) is still a major culprit
for the treatment failure, especially in leukemia. Conventional combinatorial
therapy is a major decoy to circumvent MDR, but those are frequently thwarted
by the evolving intricacies of the cancer paradigm. The advent of nanomedicine
has ushered a new era with striking pharmacokinetic drug properties far enough
to combat MDR. Physicochemical elements such as co-encapsulation, drug influx,
ratiometric drug loading, temporal sequencing on drug release, and selective
targeting moiety have been better tailored within the nanotherapeutics to
overcome MDR. This review focuses on a plethora of nanostrategies and
nanoplatforms which have been developed so far to battle MDR in leukemia.
